Abstract
Eighteen hypopituitary children, 6 girls and 12 boys, between 2 and 15 years of age, were treated for eighteen months with met-rhHg (Somatonorm). Dosage used were 0.5 IU/kg/week by daily subcutaneous (s.c.) or three tines a week intramuscular (i.m.) injections. Two of the children were twins with congenital isolated growth hormone deficiency of the type 1 A. Ore patient entered puberty six months after the treatment was started. These three children were not included in the growth evaluation.
Antibodies against met-rhGH developed in 6/8and 3/8 patients injected by s.c. and i.m. route respectively, but titers were low and did not impair growth velocity. Both twins with type 1 A GHD developed early very high antibody titers. Growth velocity fell in one but not in the other. Although no significant differences in the growth promotion effect were noted between both treatment groups antibody development was more frequently seen after s.c. met-rhGH administration. All patients increased significantly the growth velocity and final height prognosis, without local or systemic side effects.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heinrich, J., Martinez, A., Domené, H. et al. 25. GROWTH HORMONE DEFICIENCY TREATMENT WITH DNA RECOMBINANT METHMAN CROW HORMONE (MET-rhCH). Pediatr Res 23, 651 (1988). https://doi.org/10.1203/00006450-198806000-00048
Issue date:
DOI: https://doi.org/10.1203/00006450-198806000-00048
